Effect of Submaximal Doses of Semaglutide in Patients with Obesity on Metabolic Profile and Serum Levels of Adipocytokines.

IF 4.8 3区医学 Q2 CHEMISTRY, MEDICINAL

Pharmaceuticals Pub Date : 2025-09-12 DOI:10.3390/ph18091364

Martin Jozef Péč, Jakub Jurica, Monika Péčová, Norbert Nagy, Boris Focko, Zuzana Miertová, Nikola Ferencová, Ivana Ságová, Ingrid Tonhajzerová, Tomáš Bolek, Peter Galajda, Marián Mokáň, Matej Samoš

{"title":"Effect of Submaximal Doses of Semaglutide in Patients with Obesity on Metabolic Profile and Serum Levels of Adipocytokines.","authors":"Martin Jozef Péč, Jakub Jurica, Monika Péčová, Norbert Nagy, Boris Focko, Zuzana Miertová, Nikola Ferencová, Ivana Ságová, Ingrid Tonhajzerová, Tomáš Bolek, Peter Galajda, Marián Mokáň, Matej Samoš","doi":"10.3390/ph18091364","DOIUrl":null,"url":null,"abstract":"Background: Obesity is closely linked to metabolic dysfunction and systemic low-grade inflammation. Glucagon-like peptide-1 receptor agonists (GLP-1RA) are increasingly utilized for obesity treatment due to their significant metabolic benefits, including weight loss and improved glycemic control. The aim of the study was to evaluate the effect of submaximal doses of long-lasting GLP-1RA semaglutide on selected biomarkers of obesity-related inflammation, adipocytokines levels and metabolism in a real-world population of obese patients. Methods: We performed a prospective, observational study involving 32 adult patients (11 men, 21 women; mean age 49 ± 12 years; BMI 40.5 ± 7.3 kg/m2) treated with submaximal doses of semaglutide over 12 weeks, together with hypocaloric diet and increased physical activity based. We analyzed selected biomarkers including insulin, leptin, ferritin, resistin, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α) and plasminogen activator inhibitor-1 (PAI-1) before and after three months of treatment. Results: We observed significant reductions in weight, BMI, waist circumference, insulin and leptin levels (all p < 0.001). On the other hand, no significant changes were recorded in ferritin (p = 0.806), IL-6 (p = 0.607), TNF-α (p = 0.633), resistin (p = 0.250) or PAI-1 (p = 0.134) levels. Correlation analyses revealed the correlation between IL-6 and adiposity indices (BMI, waist circumference) both before and after treatment. Ferritin and PAI-1 levels positively correlated with waist circumference, while resistin showed a negative correlation with central obesity. Conclusions: Submaximal-dose GLP-1 RA therapy was associated with significant improvements in metabolic parameters and adipokine regulation, but did not affect systemic inflammatory markers within 12 weeks. Future studies with larger cohorts and longer follow-ups are needed to clarify the associations.","PeriodicalId":20198,"journal":{"name":"Pharmaceuticals","volume":"18 9","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12472706/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/ph18091364","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Obesity is closely linked to metabolic dysfunction and systemic low-grade inflammation. Glucagon-like peptide-1 receptor agonists (GLP-1RA) are increasingly utilized for obesity treatment due to their significant metabolic benefits, including weight loss and improved glycemic control. The aim of the study was to evaluate the effect of submaximal doses of long-lasting GLP-1RA semaglutide on selected biomarkers of obesity-related inflammation, adipocytokines levels and metabolism in a real-world population of obese patients. Methods: We performed a prospective, observational study involving 32 adult patients (11 men, 21 women; mean age 49 ± 12 years; BMI 40.5 ± 7.3 kg/m²) treated with submaximal doses of semaglutide over 12 weeks, together with hypocaloric diet and increased physical activity based. We analyzed selected biomarkers including insulin, leptin, ferritin, resistin, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α) and plasminogen activator inhibitor-1 (PAI-1) before and after three months of treatment. Results: We observed significant reductions in weight, BMI, waist circumference, insulin and leptin levels (all p < 0.001). On the other hand, no significant changes were recorded in ferritin (p = 0.806), IL-6 (p = 0.607), TNF-α (p = 0.633), resistin (p = 0.250) or PAI-1 (p = 0.134) levels. Correlation analyses revealed the correlation between IL-6 and adiposity indices (BMI, waist circumference) both before and after treatment. Ferritin and PAI-1 levels positively correlated with waist circumference, while resistin showed a negative correlation with central obesity. Conclusions: Submaximal-dose GLP-1 RA therapy was associated with significant improvements in metabolic parameters and adipokine regulation, but did not affect systemic inflammatory markers within 12 weeks. Future studies with larger cohorts and longer follow-ups are needed to clarify the associations.

查看原文本刊更多论文

肥胖患者服用次最大剂量的西马鲁肽对代谢谱和血清脂肪细胞因子水平的影响。

背景：肥胖与代谢功能障碍和全身性低度炎症密切相关。胰高血糖素样肽-1受体激动剂（GLP-1RA）越来越多地用于肥胖治疗，因为它们具有显著的代谢益处，包括减肥和改善血糖控制。该研究的目的是评估亚最大剂量长效GLP-1RA semaglutide对现实世界肥胖患者中肥胖相关炎症、脂肪细胞因子水平和代谢的选定生物标志物的影响。方法：我们进行了一项前瞻性观察性研究，涉及32名成年患者（11名男性，21名女性，平均年龄49±12岁，BMI 40.5±7.3 kg/m2），在12周内接受次大剂量的西马鲁肽治疗，同时进行低热量饮食和增加体力活动。我们分析了选定的生物标志物，包括胰岛素、瘦素、铁蛋白、抵抗素、白细胞介素-6 （IL-6）、肿瘤坏死因子-α (TNF-α)和纤溶酶原激活物抑制剂-1 （PAI-1）在治疗前和治疗后三个月。结果：我们观察到体重、BMI、腰围、胰岛素和瘦素水平显著降低（均p < 0.001）。另一方面，铁蛋白（p = 0.806）、IL-6 （p = 0.607）、TNF-α (p = 0.633)、抵抗素（p = 0.250）和PAI-1 （p = 0.134）水平无显著变化。相关分析显示治疗前后IL-6与肥胖指数（BMI、腰围）的相关性。铁蛋白、PAI-1水平与腰围呈正相关，抵抗素水平与中心性肥胖呈负相关。结论：次最大剂量GLP-1 RA治疗与代谢参数和脂肪因子调节的显着改善相关，但在12周内不影响全身炎症标志物。未来的研究需要更大的队列和更长时间的随访来澄清这些关联。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmaceuticals Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science

CiteScore

6.10

自引率

4.30%

发文量

1332

审稿时长

6 weeks

期刊介绍： Pharmaceuticals (ISSN 1424-8247) is an international scientific journal of medicinal chemistry and related drug sciences.Our aim is to publish updated reviews as well as research articles with comprehensive theoretical and experimental details. Short communications are also accepted; therefore, there is no restriction on the maximum length of the papers.